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The Oxford classification of IgA nephropathy (IgAN)
identified four pathological elements that were of prognostic
value and additive to known clinical and laboratory variables
in predicting patient outcome. These features are segmental
glomerulosclerosis/adhesion, mesangial hypercellularity,
endocapillary proliferation, and tubular atrophy/interstitial
fibrosis. Here, we tested the Oxford results using an
independent cohort of 187 adults and children with IgAN
from 4 centers in North America by comparing the
performance of the logistic regression model and the
predictive value of each of the four lesions in both data sets.
The cohorts had similar clinical and histological findings,
presentations, and clinicopathological correlations. During
follow-up, however, the North American cohort received
more immunosuppressive and antihypertensive therapies.
Identifying patients with a rapid decline in the rate of renal
function using the logistic model from the original study in
the validation data set was good (c-statistic 0.75), although
less precise than in the original study (0.82). Individually,
each pathological variable offered the same predictive value
in both cohorts except mesangial hypercellularity, which
was a weaker predictor. Thus, this North American cohort
validated the Oxford IgAN classification and supports its
utilization. Further studies are needed to determine the
relationship to the impact of treatment and to define the
value of the mesangial hypercellularity score.
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IgA nephropathy (IgAN) is the most common glomerular
disease worldwide. The outcome of patients with IgAN varies
greatly.1–4 Clinical variables available to physicians treating
patients with IgAN account for less than half of the variability
in outcome.1 Assessing prognosis is challenging and has
contributed to the lack of consensus regarding the manage-
ment of these patients.
The additive value of pathology features to the known
clinical parameters of proteinuria, serum creatinine, and
blood pressure in predicting long-term outcome has long
been debated.5–9 A recent international effort made by a
group of expert nephrologists and nephropathologists
using clinical, laboratory, and pathology features identified
a set of distinct pathological variables that demonstrated an
independent prognostic value in patients with IgAN, known
as the Oxford classification.10,11 In 265 cases from centers
across continents, four pathology features were found to be
of independent value in terms of predicting the outcome of
renal function: mesangial hypercellularity score (M; M0p0.5,
M140.5), the presence of endocapillary proliferation (E; E0:
absent, E1: present), segmental glomerulosclerosis/adhesion
(S; S0: absent, S1: present), and severity of tubular atrophy/
interstitial fibrosis (T; T0p25%, T1: 26–50%, T2450%).
The MEST score remained statistically significant for predic-
tion of the outcome even after taking into account the clinical
indicators available both at the time of biopsy and during the
observation period.
These findings have the potential to greatly affect
nephrologists’ approach to IgAN by improving the capacity
to identify, at the time of biopsy, high-risk-of-progression
patients in contrast to other indicators that require an
observation period before helping with prognosis.12 Defini-
tive pathological features would significantly modify not only
the approach by the physician to the individual patient but
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also the framework for designing and interpreting therapeu-
tic trials. However, before widespread adoption of this
new Oxford classification system, validation of its findings
is essential.13–15 Validation is often neglected in medical
prognostic models and has been rarely performed in kidney
disease despite its obvious importance.15 Our objective was
to assemble an independent cohort of IgAN patients to test
the validity of the Oxford pathology classification.
RESULTS
A total of 187 patients were recruited from 4 different centers
in North America (NA). In all, 44 patients (24%) were
younger than 18 years at the time of biopsy, a proportion
similar to that in the Oxford data set (Table 1). The median
year of biopsy was 2002 for the NA validation cohort versus
1997 in the Oxford derivation data set (Po0.001).
Clinical characteristics
The clinical characteristics of the validation cohort are
presented in Table 2. Compared with the Oxford derivation
cohort, there were no significant differences in age, estimated
glomerular filtration rate (eGFR), proteinuria, and mean
arterial pressure (MAP) at the time of biopsy. The NA
validation cohort contained a greater proportion of female
subjects (42 compared with 28%, P¼ 0.001).
A similar proportion of patients in both cohorts had
received immunosuppression at the time of renal biopsy
(10 NA compared with 14% Oxford, P40.1). At the time of
biopsy, 58% of patients in the NA validation data set were
on an antihypertensive medication versus 31% in the
Oxford derivation data set (P¼ 0.006). Moreover, at entry,
a higher percentage of patients was receiving renin angio-
tensin system blockade (RASB) in the NA cohort (31 versus
20%, P¼ 0.007).
The NA validation cohort also received more therapy
during the follow-up period with regard to immunosuppres-
sion (41% NA versus 29% Oxford, P¼ 0.02), RASB (87
versus 74%, P¼ 0.001), and number of anti-hypertensive
medications (median of 1.1 versus 0.9, Po0.001). Perhaps
related to these differences, the NA validation cohort
achieved a lower-average MAP than did the Oxford cohort:
92±11 mm Hg compared with 95±10 mm Hg (P¼ 0.002).
Time-average proteinuria was not different: 1.0 (0.6–1.9) g/24 h
compared with 1.1 (0.6–2.0) g/24 h. The outcomes were
similar with a rate of renal-function decline in the NA set
of 2.6±6.8 ml/min per 1.73 m2 per year compared with
3.5±8.5 ml/min per 1.73 m2 per year in the Oxford set
(P40.1). Kidney survival from a combined event was not
statistically different.
Pathology characteristics
The agreements between the two pathologists (ABF and
AMH) are shown in Table 3. The intraclass correlation
coefficients (ICCs) were higher for each of the pathology
variables assessed in comparison with the initial study, with
the exception of the mesangial score.
Table 2 | NA validation cohort: clinical characteristics at the time of biopsy and follow-up
At the time of biopsy Follow-up
Age (years) 34 (18–45) Duration of follow-up (months) 53 (36–77)
Female 42% MAP (mmHg) 92±11
Pediatric at biopsy (o18 years) 24% No. antihypertensive medications 1.1 (0.8–1.9)
Ethnicity (Caucasian/African American/Asia/Others) 69, 5, 20, 4% Treated with RASB 87%
MAP (mmHg) 96±14 Proteinuria (g/24 h) 1.0 (0.6–1.9)
Proteinuria (g/24 h) 1.7 (1.0–2.9) Immunosuppression (any) 41%
Previous immunosuppression 10% Prednisone/other 37%/24%
eGFR (ml/min per 1.73m2) 82±37 Fish oil during follow-up 61%
Previous RASB 31% Slope (ml/min per 1.73m2/years) 2.6±6.8
50% decline in eGFR 14%
End-stage renal disease 11%
Abbreviations: eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure; NA, North America; RASB, renin-angiotensin-system blockade.
Variables were expressed as mean±s.d., median with interquartile range, or percentage.
Table 3 | Intraclass correlation coefficients comparing the
derivation Oxford and the validation North American cohorts
Oxford
cohort
NA
cohort
Mesangial hypercellularity score 0.64 0.37
Percentage of total glomeruli showing segmental
sclerosis
0.46 0.94
Percentage of total glomeruli showing adhesions 0.20 0.76
Percentage of total glomeruli showing endocapillary
hypercellularity
0.57 0.87
Percentage of cortex showing tubular atrophy 0.79 0.98
Percentage of cortex showing interstitial fibrosis 0.78 0.98
Abbreviation: NA, North America.
Table 1 | Age distribution and geographical origin of the NA
validation cohort
Total Adults Children at biopsy
n 187 143 44
Vanderbilt University 55 19 36
Mayo Clinic 38 32 6
University of Alabama at Birmingham 22 21 1
University of Toronto 72 71 1
Abbreviation: NA, North America.
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The prevalence of lesions in the validation compared with
the derivation data set is shown in Figure 1. Overall, the
distributions of the pathology findings were similar in both
cohorts with the exception of the mesangial score, with a
median score of 1.07 (0.73–1.59) in the NA validation data set
compared with 0.89 (0.60–1.30) in the Oxford derivation data
set (Po0.001). All other comparisons were not statistically
different.
Clinicopathological correlations at the time of biopsy
The NA validation study found similar correlations as in the
Oxford set between the pathology findings and the clinical
assessment (eGFR, MAP, proteinuria) at the time of biopsy.
Exceptions were the lack of a statistically significant
association between proteinuria at the time of biopsy with
either the M- or the T-score, as shown in Figure 2.
Impact of pathology findings on immunosuppressive therapy
during follow-up
The administration of immunosuppression seemed to be
strongly related to the pathology findings in the NA cohort,
similar to that seen in the Oxford derivation data set
(Figure 3). In both cohorts, patients with endocapillary and
extracapillary lesions were exposed to greater immuno-
suppression than were patients without such findings, whereas
the presence of focal glomerulosclerosis/adhesion, severity
of tubulointerstitial lesions, and vascular lesions were not
correlated with treatments (data not shown). This relationship
applied somewhat differently in the two cohorts with regard to
the mesangial hypercellularity score (Figure 3).
Applicability of the Oxford model prediction rule to the
validation cohort
To validate the results in our NA data set, we derived for
every patient in each cohort the predicted probability of
a rapid rate of renal disease progression based on the
b-coefficients from the logistic regression model of the
Oxford derivation data set. The model included M-, S-, and
T-scores in addition to the known clinical predictors, initial
eGFR, follow-up time-average MAP, and time-average
proteinuria. The E-score was assessed in terms of interaction
with immunosuppressive therapy as was done in the
derivation Oxford data set (originally, the important inter-
action between the E lesion and clinical severity/treatment
allocation precluded its use in the multivariate model; see
below). To facilitate visualization, the calculated predicted
probabilities were used to create quintiles of predicted risk.
Figure 4 illustrates for each quintile the observed rate of renal-
function decline (with 95% confidence interval (95% CI) of the
mean) in each data set. Overall, the model performed well in
both cohorts validating the conclusions from the Oxford study.
Comparisons of individual pathology predictors
We also derived a new logistic regression using the same
variables from the original study. Figure 5 compares both
models and illustrates a striking resemblance for the S- and
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Figure 1 | Frequency of pathological features. Percentage of patients with each pathological feature. The six pathological features
illustrated were those with sufficient reproducibility from the Oxford study. Glom, glomeruli.
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T-scores in both data sets, but the M-score performed
differently. To further investigate the predictive value of the
M-score, we performed a survival analysis and did not find a
statistically significant reduction of a combined outcome
(hazard ratio of 0.62, 95% CI: 0.14–2.74, P40.1 in the
validation cohort compared with the Oxford derivation
hazard ratio of 0.07, 95% CI: 0.01–0.52, P¼ 0.009).
Interactions between the E lesion and immunosuppression
from both cohorts are illustrated in Figure 6. The relationship
between E lesions and the rate of renal-function decline is
evident in those who did not receive immunosuppression
and is lost in those who did. When both derivation and
validation data sets with E lesions are combined, patients
who never received immunosuppression during follow-up
had a rate of renal-function decline of 5.0±9.6 ml/min per
1.73 m2 compared with 2.3±5.4 ml/min per 1.73 m2 in
those who were treated (P¼ 0.02). This difference remained
significant after adjustment for eGFR, follow-up time-average
proteinuria, and MAP.
Added value of pathological variables on the predictive rule
The discriminative strength of the logistic model was high in
both cohorts with an area under the receiver-operating
characteristic curve (or c-statistic) of 0.75 (95% CI:
0.68–0.82) in the NA validation cohort (0.70 using clinical
variables only; 0.63 using pathology variables only). The
c-statistic was originally 0.82 (95% CI: 0.77–0.87) in the
Oxford data set (0.78 using clinical variables only; 0.70 using
pathology variables only) (Figure 7).
DISCUSSION
A recent international effort identified a set of distinct
pathological variables with prognostic value, independent of
all clinical and laboratory parameters in patients with
IgAN.10,11 Although these findings are currently insufficient
to recommend specific treatment recommendations, they
offer the possibility of a targeted approach to management
based on an improved and semi-quantified risk assessment.
Given the potential relevance of this proposed classification
and its distinctive nature compared with standard classifica-
tions, we believed that validation was essential before
recommending its implementation on a global scale. Three
of the four pathological variables identified in the Oxford
derivation cohort predicted a rapid rate of renal-function
decline in the NA validation data set, supporting the original
findings. Additional support of its validity is the closeness of
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fit across the quintiles of risk when the observed-to-predicted
rate of renal-function decline is compared in both cohorts
(Figure 4). The exception was the mesangial hypercellularity
score (M-score), with a predictive value that underperformed
in the NA data set. Although the added value of pathology
to longitudinal clinical assessment may seem moderate
(Figure 7), biopsy findings have the advantage of immediate
long-term predictive value.
The M-score deserves additional comment. Not only was
its long-term predictive value reduced but also the cross-
sectional correlation with proteinuria at the time of biopsy
was absent. Possible explanations, other than a spurious
relationship identified in the derivation study, are multiple.
The lower ICC observed for this variable in this study may
have resulted in error in measurement, leading to a non-
significant finding. Alternative explanations include the
different therapeutic strategies in the two cohorts, such as
the greater anti-hypertensive treatment and RASB in the NA
cohort, both during follow-up and before renal biopsy.
Certainly others studies have shown that the effect of the
renin-angiotensin system is associated with mesangial cell
inhibition and prevention of renal-function decline in both
human and experimental glomerulonephritis.16,17 As in
the derivation data set, we found an interaction between the
E-score and the use of immunosuppressive therapy and
the rate of renal-function decline in the validation cohort. In
the original derivation study, because of the small number of
subjects, we could not determine the independent predictive
value of the E-score, given this important potential
confounder of treatment effect. However, by combining the
two cohorts, we were able to provide further evidence that
supports the independent predictive value of endocapillary
proliferation (Figure 6). Our findings strongly corroborate
the value of the inclusion of the E-score in the Oxford
classification and address previous questions in this regard.13
These results also illustrate the potential role of renal biopsy
findings in the selection of IgA patients requiring aggressive
therapy. Although a recent study did not show a predictive
value of endocapillary lesions, the prevalence of such findings
was not reported, and potential interaction with immuno-
suppression was not assessed.18
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Prediction models estimate an outcome using a mathe-
matical equation combining multiple variables. Three steps
guide their clinical utility: (1) development of a prediction
equation, (2) validation of the accuracy and generalizability
of findings, and (3) studying the clinical impact on physician
behavior and patient outcome after implementation in
daily practice. Although articles proposing predictive models
based on risk factors are numerous, very few have been
validated or have addressed how their implementation has
affected patient care.19 This failure to validate has potential
serious consequences, because premature implementation
of an imprecise model or inappropriate generalization of
conclusions can cause harm to patients, and can misdirect
treatment algorithms and clinical trials.
True validation of any type is complex and has its own set
of rules often not understood or followed. There are also
various methodologies to test validity.20 Internal validation
can be performed by splitting a study cohort into two groups
and using one for validation. More sophisticated methods
repeat this procedure (bootstrap) many times on random
data subsets to identify a more robust model.21 External
validation is a superior method but does require the use of a
new database, ideally from different centers and scientists.15
A validation study classically requires an adequate sample of a
different but related patient population as that found in the
original derivation cohort. We followed our original Oxford
inclusion and exclusion criteria to maintain this element of
validation in our study. We recognize that, as discussed in the
original paper, the elimination of the subsets of the IgAN
patient population displaying extremes of the histological
and/or clinical features, that is, those with very rapid
progression or with no significant proteinuria may mean
that our results cannot be applied to these subsets. It may also
not apply to other ethnicities, such as African Americans,
Hispanics, and Asians.
There are two additional elements that can be examined
to strengthen the validation process; these include studying
the predictive value of a model across time and across
geographic boundaries. There was a 5-year difference
between the time of biopsy in the Oxford derivation cohort
(1997) versus the North American validation cohort (2002),
thus fulfilling this criterion. It is likely that this resulted in the
previously discussed differences in terms of blood pressure
medications, RASB usage, and immunosuppression; however,
despite these changes, the predictive capacity of the Oxford
classification remained largely intact. We also fulfill the
different origins of the data elements as our NA cohort is
geographically different from the derivation data set being
restricted to a North American base versus a more varied
origin in the Oxford derivation cohort.
In general, any classification needs to be reproducible.
This capacity for replication of the interpretation of the
pathology findings to span a wide range of nephropatho-
logists, from academic specialists to those in the community,
has been a notable limitation in many previous studies that
have attempted to quantify the added value of pathology in
renal diseases.22–25 In all, 10 of the 24 initial variables from
the original study were judged to be insufficiently reprodu-
cible for further analysis; after assessing co-linearity, only 6
were sufficiently independent from one another to warrant
predictive testing.11 In our NA cohort, the ICCs were very
good and higher than those in the Oxford derivation data set.
This finding supports its reproducibility. The agreement
based on the cutoffs proposed by the Oxford classification
was also high. Part of this is because of the simplicity of the
chosen variables. Two, namely the presence of endocapillary
proliferation or segmental glomerulosclerosis, are based on a
simple ‘present’ or ‘absent’ assessment. Thus, a single glome-
rulus with either of these lesions correlated with a worse
prognosis during follow-up. Tubulointerstitial fibrosis, asses-
sed with a semi-quantitative score with the Oxford classifi-
cation, was also robustly scored in this study. Different
morphometric approaches and various staining parameters
have been advocated,26 but the semi-quantitative ‘eyeballing’
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assessment on a light microscopy slide by an experienced
pathologist is a straightforward, reliable, and robust morpho-
logical parameter.27 The ICC for mesangial proliferation was
lower than that in the derivation data set. This could have
occurred because the scoring process is more time-consuming
and complex compared with the other features as it involves
counting mesangial cell nuclei in each glomerulus.11
In large part, this study validates the Oxford classification
in IgAN and provides strong support for a more widespread
adoption of this model in routine pathology practice. In
addition, the validation process indicates that utilization of
this new classification will improve the ability to identify
early those patients who are most likely to progress to renal
failure and may respond to immunosuppressive treatment.
The classification should significantly modify not only our
approach to the individual patient but also our framework
for designing future clinical trials in IgAN.
MATERIALS AND METHODS
Design
This is a retrospective study of 187 patients with biopsy-proven
IgAN followed in 1 of 4 North American centers: the University of
Toronto Glomerulonephritis Registry, the University of Alabama at
Birmingham, the Vanderbilt University Medical Center in Tennes-
see, and the Mayo Clinic in Minnesota.
Inclusion criteria and clinical data set
The inclusion criteria as required in validation studies were identical
to those of the initial study. Patients of any age with native-kidney
biopsy-proven IgAN were included, provided their initial eGFR was
X30 ml/min per 1.73 m2, proteinuria was X0.5 g/24 h (X0.5 g/24 h
per 1.73 m2 in children), follow-up was at least 12 months, and an
adequate renal biopsy was available. Patients with isolated
hematuria, Henoch-Schoenlein purpura, or co-existing conditions
such as diabetes mellitus were excluded.
Demographics collected included gender, ethnicity, and age at
the time of biopsy. Children were defined as patients agedo18 years
at biopsy. Clinical parameters collected initially (within 3 months of
the date of biopsy) and during follow-up included systolic and
diastolic blood pressures, weight, height, serum creatinine, and 24-h
urine protein or urine protein-to-creatinine ratio. To provide
consistency between measurements in adults and children, protei-
nuria was expressed in g/24 h per 1.73 m2 in children and g/24 h in
adults. Drug exposure was also collected, including immuno-
suppressive agents, fish oil, and the number and type of anti-
hypertensive medications, including angiotensin-converting enzyme
inhibitor and angiotensin receptor blocker. Data verification
occurred by communication between the two of the writing
committee authors (ST and HNR) and the contributing centers.
Pathology data set
Biopsy adequacy was defined as a minimum of eight glomeruli
available for examination by light microscopy. IgAN was confirmed
as predominant or codominant immunoglobulin in the mesangial
deposits. Two experienced renal pathologists, both members of the
original Oxford study, independently scored every feature according
to the full Oxford score sheet.11 The first pathologist scoring a given
case chose the most representative section within biopsy slides.
This section was marked and independently scored by the second
pathologist. We derived an MEST score based on these results.
Discordant scores were observed in a minority of cases and they
were resolved by a head-to-head meeting between the pathologists
(ABF and AMH).
Definitions
The eGFR was calculated using the four-variable Modification of
Diet in Renal Disease Study formula in adults and the Schwartz
formula in children (using the constant 0.55). End-stage renal
disease was defined as eGFR o15 ml/min per 1.73 m2. A combined
event was defined by a 50% reduction in eGFR or end-stage renal
disease. MAP was defined as diastolic pressure plus a third of the
pulse pressure. For each patient, average MAP and proteinuria were
determined for each year of observation. Time-average MAP and
proteinuria represent the average of these annual values. Immuno-
suppressive treatment is reported as intent to treat, regardless of the
type or duration of therapy. RASB indicates any exposure to
angiotensin-converting enzyme inhibitor, angiotensin receptor
blocker, or both.
Statistical analysis
Normally distributed variables were expressed as mean±s.d. and
compared using Student’s t-test or one-way ANOVA (analysis of
variance). Non-parametric variables were expressed as median with
interquartile range and compared using either Mann–Whitney or
Kruskal–Wallis test. Categorical variables were expressed in percen-
tages and compared using the Pearson w2 test.
Reproducibility was assessed for each variable of the extended
pathology data set using the ICC, a measure of reproducibility
applicable to multiple raters. By convention, an ICC of 0.40–0.59 is
moderate inter-rater reliability; 0.60–0.79, substantial; and X0.80,
outstanding.28
The rate of renal-function decline (slope) was used as the main
outcome. It was determined by fitting a straight line through available
data for eGFR using the principle of least squares. This line was plotted
and visually examined in each patient. Obvious outliers were censored.
The original study used three multivariate methodologies to
assess the independent value of pathology findings: linear regression
(slope), logistic regression (slope categorized by slow or rapid rate of
renal-function decline based on the median value), and Cox
regression (survival from either end-stage renal disease or a 50%
decrease in eGFR). However, the slope distribution in this cohort
was flatter and more skewed than the normal ‘bell-shaped’ curve;
hence, the assumption of normality could not be met and therefore
linear regression analysis was not applied. We had also assessed
kidney survival from a 50% decrease in eGFR or ERSD but could
not adjust for multiple variables in the NA cohort because the
number of these events was too low in comparison with the Oxford
cohort. Therefore, we could only use the logistic model to test
whether the added value of pathology features remained inde-
pendent of the clinical assessment.
Validation of the Oxford clinicopathological classification using
this new cohort was tested in a series of predefined successive steps:
(1) Using the logistic regression equation from the Oxford data set,
we calculated for each patient from both cohorts the predicted
probability of a rapid rate of renal-disease progression.
(2) We then categorized these predicted probabilities into five
groups with increasing risk (quintiles) for each data set.
(3) We compared the observed rate of renal-function decline among
quintiles. A consistent relationship between predicted risk and
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observed rate of renal-function decline in both cohorts validates
the Oxford logistic model.
(4) To further address differences between the two data sets and to
determine whether any of the specific pathological findings
differed in the predictive value compared with the original,
we performed a new logistic regression on the validation data
set using the same variables as in the initial Oxford model and
compared graphically the adjusted odds ratio of each patho-
logical variable with those reported in the original classification
paper.
(5) Finally, we calculated the area under the receiver-operating
characteristic curves (c-statistic) from the Oxford and North
American logistic regression models.
Survival from a 50% reduction in renal function or end-stage
renal disease was performed using the log-rank test.
All P-values were two-tailed, and values o0.05 were considered
statistically significant. CIs included 95% of predicted values.
Analyses were carried out using SPSS software (version 16, SPSS,
Chicago, IL).
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